Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT00553618

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients (DTIC)

Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma

Sponsor: James Graham Brown Cancer Center

Conditions Metastatic Melanoma

Interventions Proleukin and Dacarbazine

Updated 7 times since 2017 Last updated: Oct 22, 2021 Started: Aug 31, 2007 Primary completion: Aug 31, 2025 Completion: Aug 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Melanoma, this trial is ongoing. The trial is conducted by James Graham Brown Cancer Center and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Nov 2021 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

James Graham Brown Cancer Center
University of Louisville

Data source: University of Louisville

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Louisville, United States